Risk Factors for Microscopic Colitis

显微镜下结肠炎的危险因素

基本信息

  • 批准号:
    10731477
  • 负责人:
  • 金额:
    $ 65.36万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-12-01 至 2026-08-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Microscopic colitis is the most common cause of chronic watery diarrhea in older adults. The symptoms of this disease are debilitating. Patients describe isolation and withdrawal from social life and activities. Treatment is limited to expensive therapies that are sometimes ineffective. Disease relapse is common after medications are stopped. Although the incidence is comparable to inflammatory bowel disease, the disease has received much less research attention. A number of medications (PPIs, NSAIDs, statins, SSRIs) have been linked with microscopic colitis. Although guidelines suggest discontinuing these medications as the initial step in treatment, the evidence supporting this recommendation is weak. The first phase of this study enrolled patients with microscopic colitis and diarrhea controls. Contrary to existing beliefs, there was no association with medications previously linked to microscopic colitis. There was a strong inverse association with obesity and exogenous hormones. Amplicon sequencing by 16S rRNA demonstrated that microbiome alpha-diversity was significantly lower in microscopic colitis cases compared to controls. Several taxa were enriched in cases. The present study is designed to extend and expand on the initial findings. The aims of the proposed case-control study are: 1) To investigate medications, oral contraceptives, postmenopausal hormones and obesity by comparing microscopic colitis cases to two comparison groups – patients referred for colonoscopy for diarrhea and colonoscopy for colorectal cancer screening. 2) To use shotgun metagenomic sequencing to gain insight into biodiversity and function. 3) To use RNA sequencing of mucosal samples from microscopic colitis patients, diarrhea controls and screening controls to reveal genetic signatures associated with microscopic colitis and discover potential druggable disease targets. The study will enroll 150 microscopic colitis cases, 300 diarrhea controls and 300 screening colonoscopy controls. Biopsies from the colon will be used to evaluate adherent bacterial organisms and to conduct RNAseq experiments in 100 microscopic colitis cases, 100 diarrhea controls and 100 screening colonoscopy controls. Structured telephone interviews will obtain detailed dietary, medication and lifestyle information on study subjects. The prospective data collection corrects important limitations of prior research by others. The addition of a second control group could provide more definitive evidence to avoid unnecessarily stopping therapeutically important medications (PPIs, NSAIDs, statins, SSRIs). Shotgun metagenomics could provide information on microbial etiology or functional genes potentially leading to strategies to prevent or treat the disease. The study will improve our understanding of risk factors, set the stage for more scientifically grounded future research, and potentially suggest new interventions for a disease that is currently poorly understood.
项目摘要 显微镜下结肠炎是老年人慢性水样腹泻的最常见原因。这种病的症状 疾病使人衰弱。患者描述了孤立和退出社会生活和活动。治疗是 仅限于昂贵的治疗,有时无效。药物治疗后疾病复发很常见 都停止了虽然发病率与炎症性肠病相当,但该疾病已收到 更少的研究关注。许多药物(PPI、NSAID、他汀类药物、SSRI)与 显微镜下结肠炎虽然指南建议停止这些药物作为第一步, 然而,支持这一建议的证据并不充分。这项研究的第一阶段招募了 用显微镜检查结肠炎和腹泻与现有的观点相反, 以前与显微镜下结肠炎有关的药物。与肥胖有很强的负相关性, 外源激素通过16 S rRNA扩增子测序表明,微生物组α多样性是 与对照组相比,显微镜下结肠炎病例显著降低。几个分类群的情况下,丰富。的 本研究旨在扩展和扩大初步调查结果。病例对照研究的目的 研究内容为:1)调查药物、口服避孕药、绝经后激素与肥胖的关系, 将显微镜下结肠炎病例与两个对照组进行比较-因腹泻而接受结肠镜检查的患者 和结肠镜检查进行结肠直肠癌筛查。2)使用鸟枪式宏基因组测序 生物多样性和功能。3)为了使用来自显微镜下结肠炎患者的粘膜样品的RNA测序, 腹泻对照和筛选对照,以揭示与显微镜下结肠炎相关的遗传特征, 发现潜在的可药物治疗的疾病靶点。该研究将招募150例显微镜下结肠炎病例,300例腹泻病例, 对照组和300例结肠镜检查筛查对照组。结肠活检将用于评价粘附 在100例显微镜下结肠炎病例、100例腹泻病例中进行RNAseq实验, 对照组和100例结肠镜检查筛查对照组。结构化的电话采访将获得详细的饮食, 研究对象的药物和生活方式信息。前瞻性数据收集纠正重要 其他人先前研究的局限性。增加第二个对照组可以提供更明确的 避免不必要地停止治疗重要药物(PPI,NSAID,他汀类药物, SSRIs)。鸟枪式宏基因组学可以提供微生物病原学或功能基因的信息, 从而导致预防或治疗该疾病的策略。这项研究将提高我们对风险因素的理解, 为更科学的未来研究奠定了基础,并可能提出新的干预措施, 这种疾病目前还知之甚少。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ROBERT S. SANDLER其他文献

ROBERT S. SANDLER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ROBERT S. SANDLER', 18)}}的其他基金

INFLAMMATION, OBESITY AND RISK OF COLORECTAL ADENOMAS
炎症、肥胖和结直肠腺瘤的风险
  • 批准号:
    7939993
  • 财政年份:
    2009
  • 资助金额:
    $ 65.36万
  • 项目类别:
INFLAMMATION, OBESITY AND RISK OF COLORECTAL ADENOMAS
炎症、肥胖和结直肠腺瘤的风险
  • 批准号:
    7933193
  • 财政年份:
    2009
  • 资助金额:
    $ 65.36万
  • 项目类别:
CLINICAL TRIAL: VITAMIN D/CALCIUM POLYP PREVENTION STUDY
临床试验:维生素 D/钙预防息肉研究
  • 批准号:
    7716789
  • 财政年份:
    2008
  • 资助金额:
    $ 65.36万
  • 项目类别:
VITAMIN D/CALCIUM POLYP PREVENTION STUDY
维生素 D/钙预防息肉研究
  • 批准号:
    7625566
  • 财政年份:
    2006
  • 资助金额:
    $ 65.36万
  • 项目类别:
VITAMIN D/CALCIUM POLYP PREVENTION STUDY
维生素 D/钙预防息肉研究
  • 批准号:
    7377510
  • 财政年份:
    2005
  • 资助金额:
    $ 65.36万
  • 项目类别:
ASPIRIN AND FOLIC ACID IN THE PREVENTION OF COLON POLYPS
阿司匹林和叶酸预防结肠息肉
  • 批准号:
    7200159
  • 财政年份:
    2004
  • 资助金额:
    $ 65.36万
  • 项目类别:
PROGNOSTIC & PREDICTIVE FACTORS IN OUTCOME OF PATIENTS WITH COLORECTAL CANCER:
预测
  • 批准号:
    6791840
  • 财政年份:
    2004
  • 资助金额:
    $ 65.36万
  • 项目类别:
CORE--BIOSTATISTICS AND DATA MANAGEMENT
核心——生物统计和数据管理
  • 批准号:
    6827146
  • 财政年份:
    2004
  • 资助金额:
    $ 65.36万
  • 项目类别:
VITAMIN D/CALCIUM POLYP PREVENTION STUDY
维生素 D/钙预防息肉研究
  • 批准号:
    7200319
  • 财政年份:
    2004
  • 资助金额:
    $ 65.36万
  • 项目类别:
CORE--ADMINISTRATIVE
核心——行政
  • 批准号:
    6827145
  • 财政年份:
    2004
  • 资助金额:
    $ 65.36万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 65.36万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 65.36万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 65.36万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 65.36万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 65.36万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 65.36万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 65.36万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 65.36万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 65.36万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 65.36万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了